A Double-blind, Randomized, Comparative, Multicenter, Exploratory, and Placebo-controlled Phase II Trial of FOLFIRI Plus MSC1936369B or Placebo With a Safety run-in Part as Second-line Treatment of Metastatic K Ras Mutated Colorectal Cancer Subjects

Trial Profile

A Double-blind, Randomized, Comparative, Multicenter, Exploratory, and Placebo-controlled Phase II Trial of FOLFIRI Plus MSC1936369B or Placebo With a Safety run-in Part as Second-line Treatment of Metastatic K Ras Mutated Colorectal Cancer Subjects

Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 21 Oct 2016

At a glance

  • Drugs Pimasertib (Primary) ; Fluorouracil; Folinic acid; Irinotecan
  • Indications Colon cancer; Colorectal cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors EMD Serono
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 01 Apr 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 05 Jan 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top